TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05647317

Intervention type: OTHER
Group type: OTHER
Intervention: A combination of a provider-facing desktop and mobile application with a patient-facing mobile application
Description: A combination of a provider-facing desktop and mobile application with a patient-facing mobile application that is integrated with a remote blood pressure cuff, heart rate monitor, and scale.
Study: NCT04683640

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GABA
Description: Daily oral GABA for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral Placebo for 4 weeks
Study: NCT05024227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: nursing education interventions (including e-health platform assistance)
Description: Nursing education intervention: Researchers use teaching, consultation and other methods to give individual cases planned learning to meet individual needs, providing 1. What is an environmental hormone-plasticizer; 2. Common types of environmental hormones (such as plasticizers) and Uses 3. Environmental hormones-sources of plasticizers 4. Environmental hormones-plasticizers harm to the human body 5. How to avoid the common environmental hormones-plasticizers and other related health education in life, and use the electronic platform to assist nursing education conduct.
Study: NCT06154486

Intervention type: DRUG
Intervention: semaglutide use
Description: patient using semaglutide for at least 7 days
Study: NCT04579133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg BID OR 200 mg BID (if glomerular filtration rate \[GFR\] 31 to 50 mL/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV
Study: NCT05938231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastric Bypass Stent System
Description: Subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy. Following a 3-month treatment period, the device is removed, and subjects are followed for 6 months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dietary Intervention
Description: The patients in the trial group or in the control group,have 9-month dietary intervention in the syudy period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: The patients in the trial group or in the control group,have 9-month dietary intervention in the syudy period.
Study: NCT05902923

Intervention type: PROCEDURE
Intervention: endovascular intervention
Description: endovascular intervention
Study: NCT04294563

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanut Protein Powder
Description: Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care by Surgeon and Physical Therapist
Description: Patient will receive standard care from treating physicians and physical therapists pre- and post-operatively

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care by Surgeon and Physical Therapist
Description: Patient will receive standard care from treating physicians and physical therapists pre- and post-operatively
Study: NCT05300074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: IMT is performed with an IMT Threshold flute that can be adjusted according to the MIP. The training resistance start at 60% MIP and is calculated weekly and end (if tolerated) at 80 % MIP.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: IMT is performed with an IMT Threshold flute that can be adjusted according to the MIP. The training resistance start at 60% MIP and is calculated weekly and end (if tolerated) at 80 % MIP.
Study: NCT05277129

Intervention type: OTHER
Intervention: Analysis of post-stroke immune responses
Description: Analysis of immune responses in peripheral blood
Study: NCT06200064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-stretching exercise group
Description: Static neck muscle self-stretching exercises were performed for 30 min. after the TENS procedure. Every muscle in the neck region (head rotator cuff, neck stair muscles, upper part of the trapezius muscle, scapula levator muscle, semiscapular neck muscle, upper oblique head muscle, girdle head and neck muscles, and deep anterior neck flexor muscles) were stretched 3 times for 30 seconds per muscle group. While performing exercises, the subjects applied resistance with their hands. All exercises were performed without causing pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-isometric relaxation exercise group
Description: The investigators used one of the autogenic inhibition techniques - post-isometric relaxation (PIR), known as the muscle contraction-relaxation technique, during which, the subject is lying on his back, he is asked to press his head in the specified direction (50% of the subject's maximum pressure force). to the resistance provided by the therapist. During the press, resistance was provided for 10 seconds and followed by a passive stretch of the muscle in the opposite direction of movement. A total of 5 repetitions are performed for each muscle with a 5-second break. All movements are performed without causing pain of more than moderate intensity.
Study: NCT05895565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMG1015
Description: Including 3 dose levels: level 1, level 2 and level 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PMG1015 placebo
Description: Including 2 dose levels corresponding to PMG1015 level 1 and level 2, with no placebo group set for PMG1015 level 3
Study: NCT06135077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-PRF alone
Description: T-PRF is the material to be tested in this study as an alternative to classical bone graft

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: T-PRF/Xenograft
Description: One part of T-PRF will be divided into minute pieces to be mixed with xenograft
Study: NCT01188213

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methylsulfonylmethane (MSM)
Study: NCT05821751

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inulin
Description: Inulin will be given to enrolled patients according to manufacturer label indications.~ICIs (i.e. nivolumab and pembrolizumab) alone or in combination with chemotherapy, if clinically indicated, and their administration scheduling will be planned as per international and local guidelines.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inulin
Description: Inulin will be given to enrolled patients according to manufacturer label indications.~ICIs (i.e. nivolumab and pembrolizumab) alone or in combination with chemotherapy, if clinically indicated, and their administration scheduling will be planned as per international and local guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
Study: NCT04742322

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium Lactis CCT7858
Description: Probiotic B Lactis

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin
Study: NCT06064513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: verbal empathy training
Description: Empathy training will be given to nurses in the control group using face-to-face interview technique. In this training, the researcher will explain verbally what empathy is and how to make an empathetic approach to sick individuals. The training will be given to nurses twice, one week apart, at their own time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video based empathy training
Description: Nurses in the video group will be shown a video recording about empathy. Nurses will be allowed to watch the training video twice, with an interval of one week. After the empathy training is completed, the evaluation phase will begin. For this purpose, 2 weeks and 4 weeks after the end of the last training, nurses in both study groups will be asked to fill out the Integrative Nursing Competency Scale and Empathy Level Determination Scale. In the study, a comparison of nurses' pre-test and post-test answers will be made to evaluate the effectiveness of video-based education.
Study: NCT06394440

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Self-Adhesive Bulkfill Composite (Surefil One)
Description: It is a new self-adhesive bulkfill composite that requires no previous adhesive steps.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Self-Adhesive Bulkfill Composite (Surefil One)
Description: It is a new self-adhesive bulkfill composite that requires no previous adhesive steps.
Study: NCT06165939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection
Description: Ultrasound-guided intra-articular corticosteroid injection treatment in the shoulder joint (2 ml SHINCORT INJ 10 MG/ML + 2 ml 2% Xylocaine) is performed once for the patient at the first week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intra-articular corticosteroid injection
Description: Ultrasound-guided intra-articular corticosteroid injection treatment in the shoulder joint (2 ml SHINCORT INJ 10 MG/ML + 2 ml 2% Xylocaine) is performed once for the patient at the first week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrodilation with 15% hypertonic dextrose
Description: The second round of ultrasound-guided shoulder joint injection is performed at the fourth week during the follow-up period and the injectate is 15% hypertonic dextrose (6 ml 50% Dextrose + 2 ml 2% Xylocaine + 12 ml normal saline, totaling 20 ml).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydrodilation with Normal saline
Description: The second round of ultrasound-guided shoulder joint injection is performed at the fourth week during the follow-up period and the injectate is Normal saline (2 ml 2% Xylocaine + 18 ml normal saline, totaling 20 ml).
Study: NCT05751291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Pericapsular Nerve Group (PENG) Block: 20 mL of 0.25% bupivacaine will be injected in increments while observing for an adequate fluid spread in this plane. Fascia Iliaca Compartment (FIC) Block: 20 mL of 0.25% bupivacaine will be injected until it spreads.~laterally toward the iliac spine and medially toward the femoral nerve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Pericapsular Nerve Group (PENG) Block: 20 mL of 0.25% bupivacaine will be injected in increments while observing for an adequate fluid spread in this plane. Fascia Iliaca Compartment (FIC) Block: 20 mL of 0.25% bupivacaine will be injected until it spreads.~laterally toward the iliac spine and medially toward the femoral nerve.
Study: NCT05509933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: budesonide starting day 5 after transplant
Study: NCT04906447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Relaxation
Description: Guided relaxation uses the mind to reduce pain, promote well-being, and improve physical function. Guided relaxation is a state of concentration and focused attention that gives people more control over their pain experience and its impact and an increased sense of well-being.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a body-based therapy that includes the insertion of thin needles at strategic points on the body that has been proven effective for reducing pain.
Study: NCT05601791

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Steroid Injection
Description: Epidural Steroid Injection transforaminal approach Drug: midazolam, fentanyl, lidocaine, levobupivacaine, methilprednisoloneacetat

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Steroid Injection
Description: Epidural Steroid Injection transforaminal approach Drug: midazolam, fentanyl, lidocaine, levobupivacaine, methilprednisoloneacetat

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Laser Disc Decompression
Description: Percutaneous Laser Disc Decompression Drug: midazolam, fentanyl, lidocaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Laser Disc Decompression
Description: Percutaneous Laser Disc Decompression Drug: midazolam, fentanyl, lidocaine
Study: NCT05804266

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coventional coagulation
Description: In the conventional group, the haemostasis of vessels will be performed with the conventional coagulation technique under CO2 insufflation. First, submucosal fibres surrounding a blood vessel will be dissected and the vessel will be isolated. After, both sides of the isolated vessel will be coagulated using SWIFT COAG E3, 89 W for POEM and SWIFT COAG E4, 124 W for ESD until the blood vessel turns white and can be finally cut.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Underwater coagulation
Description: In the treatment group, the prophylactic haemostasis of vessels will be accomplished by the underwater coagulation technique. First, physiological solution will be instilled until there is no more air around the blood vessel. Then, the vessel will be coagulated using SWIFT COAG E3, 89 W for POEM and SWIFT COAG E4, 124 W for ESD until it turns white and, after the removal of all the physiological solution, can be finally cut.
Study: NCT05380492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VOY-101
Description: Intravitreal injection of VOY-101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VOY-101
Description: Intravitreal injection of VOY-101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VOY-101
Description: Intravitreal injection of VOY-101
Study: NCT06087016

Intervention type: OTHER
Intervention: Urine vibrational analysis
Description: Urine vibrational analysis

Intervention type: OTHER
Intervention: Urine vibrational analysis
Description: Urine vibrational analysis
Study: NCT04589754

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sintilimab plus chemotherapy
Description: AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks; sintilimab (10ml; 100mg) was administered intravenously every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy
Description: AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks; sintilimab (10ml; 100mg) was administered intravenously every 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adriamycin-based chemotherapy
Description: AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin-based chemotherapy
Description: AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.
Study: NCT05924685

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccination
Description: Vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccination
Description: Vaccination
Study: NCT05866887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep ALL Night
Description: Sleep intervention program comprised of a sleep action plan tool and interactive psychoeducation website.
Study: NCT04822623

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI examination

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI examination

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI examination
Study: NCT06266819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chewing gum
Description: In addition to the routine treatment plan, mint-flavored gum will be chewed for an average of 15 minutes at least 4 hours after the antiemetic application.
Study: NCT05291767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: participants will consume a high fat (intervention) or high carbohydrate (control) meal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: participants will exercise with medium intensity under supervision for 30 minutes (intervention) or rest (control) after consuming the meal.
Study: NCT06251609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone 2 MG
Description: The intervention consists of naloxone 2mg (2ml of 1mg/ml solution) administered by EMS personnel via the IV or IO route. The study intervention will be administered immediately (within 5 minutes) following the first dose of epinephrine. When naloxone hydrochloride is administered intravenously, the onset of action is generally apparent within two minutes. The naloxone will be administered following the first dose of epinephrine. The control is saline 2ml will be supplied in pre-filled syringes within numbered trial treatment packs. They will be identical in appearance to the naloxone syringes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 2ml
Description: Placebo
Study: NCT06117098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Individual lifestyle intervention via an mobile application

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based lifestyle intervention at a Healthy Lifestyle Centre + mobile application
Description: Group-based lifestyle intervention at a Healthy Lifestyle Centre + mobile application

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-based lifestyle intervention
Description: Group-based life style intervention at a Healthy Lifestyle Centre (ususal care)
Study: NCT05127369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dental pulp mesenchymal cell injection
Description: Dental pulp mesenchymal cell injection was administered intravenously on D1, D15 (2 weeks), D29 (4 weeks) and d43 (6 weeks); Fluoxetine hydrochloride capsule / simulant was administered orally daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dental pulp mesenchymal cell vehicle
Description: Dental pulp mesenchymal cell vehicle was administered intravenously on D1, D15 (2 weeks), D29 (4 weeks) and d43 (6 weeks); Fluoxetine hydrochloride capsule / simulant was administered orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine hydrochloride capsule
Description: fluoxetine hydrochloride capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine hydrochloride capsule
Description: fluoxetine hydrochloride capsule
Study: NCT04916522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.5 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study: NCT05394376

Intervention type: OTHER
Group type: OTHER
Intervention: Level of noise and environment (public vs private) while taking blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the level of noise in their environment changes and whether they are in a public or private setting prior to each set of measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Level of noise and environment (public vs private) while taking blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the level of noise in their environment changes and whether they are in a public or private setting prior to each set of measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Level of noise and environment (public vs private) while taking blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the level of noise in their environment changes and whether they are in a public or private setting prior to each set of measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Level of noise and environment (public vs private) while taking blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the level of noise in their environment changes and whether they are in a public or private setting prior to each set of measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Level of noise and environment (public vs private) while taking blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the level of noise in their environment changes and whether they are in a public or private setting prior to each set of measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Level of noise and environment (public vs private) while taking blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the level of noise in their environment changes and whether they are in a public or private setting prior to each set of measurements.
Study: NCT05647850

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention